

### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-41. Cancelled.

Claim 42. A method for reducing the levels of A $\beta$  peptide in a mammal, comprising administering a therapeutically effective amount of a soluble Nogo receptor antagonist.

Claim 43. The method of claim 42, wherein the levels of A $\beta$  peptide are elevated in association with a disease, disorder or condition.

Claim 44. The method of claim 43, wherein said disease, disorder or condition is Alzheimer's disease.

Claim 45. The method of claim 42, wherein the soluble Nogo receptor polypeptide is administered by bolus injection or chronic infusion.

Claim 46. The method of claim 45, wherein the soluble Nogo receptor polypeptide is administered directly into the central nervous system.

Claim 47. The method of claim 42, wherein the soluble Nogo receptor polypeptide is a soluble form of a mammalian NgR1.

Claim 48. The method of claim 47, wherein the soluble form of a mammalian NgR1 comprises a peptide selected from the group consisting of:

- (a) amino acids 26 to 310 of human NgR1 (SEQ ID NO:3) with up to ten conservative amino acid substitutions;
- (b) amino acids 26 to 344 of human NgR1 (SEQ ID NO:4) with up to ten conservative amino acid substitutions;

- (c) amino acids 27 to 310 of rat NgR1 (SEQ ID NO:5) with up to ten conservative amino acid substitutions; and
- (d) amino acids 27 to 344 of rat NgR1 (SEQ ID NO:6) with up to ten conservative amino acid substitutions.

Claim 49. The method of claim 48, wherein the soluble form of a mammalian NgR1 comprises a peptide selected from the group consisting of:

- (a) amino acids 26 to 310 of human NgR1 (SEQ ID NO:3);
- (b) amino acids 26 to 344 of human NgR1 (SEQ ID NO:4);
- (c) amino acids 27 to 310 of rat NgR1 (SEQ ID NO:5); and
- (d) amino acids 27 to 344 of rat NgR1 (SEQ ID NO:6).

Claim 50. The method of claim 47, wherein the soluble form of a mammalian NgR1 further comprises a fusion moiety.

Claim 51. The method of claim 42, wherein the therapeutically effective amount is from 0.001 mg/kg to 10 mg/kg of soluble Nogo receptor polypeptide.

Claim 52. A method of preventing or treating a disease, disorder or condition associated with plaques of A $\beta$  peptide in a mammal, comprising administering a therapeutically effective amount of a soluble Nogo receptor polypeptide.

Claim 53. The method of claim 52, wherein said disease, disorder or condition is Alzheimer's Disease.

Claim 54. The method of claim 52, wherein the soluble Nogo receptor polypeptide is administered by bolus injection or chronic infusion.

Claim 55. The method of claim 54, wherein the soluble Nogo receptor polypeptide is administered directly into the central nervous system.

Claim 56. The method of claim 52, wherein the soluble Nogo receptor polypeptide comprises a soluble form of a mammalian NgR1.

Claim 57. The method of claim 56, wherein the soluble form of a mammalian NgR1 comprises a peptide selected from the group consisting of:

- (a) amino acids 26 to 310 of human NgR1 (SEQ ID NO:3) with up to ten conservative amino acid substitutions;
- (b) amino acids 26 to 344 of human NgR1 (SEQ ID NO:4) with up to ten conservative amino acid substitutions;
- (c) amino acids 27 to 310 of rat NgR1 (SEQ ID NO:5) with up to ten conservative amino acid substitutions; and
- (d) amino acids 27 to 344 of rat NgR1 (SEQ ID NO:6) with up to ten conservative amino acid substitutions.

Claim 58. The method of claim 57, wherein the soluble form of a mammalian NgR1 comprises a peptide selected from the group consisting of:

- (a) amino acids 26 to 310 of human NgR1 (SEQ ID NO:3);
- (b) amino acids 26 to 344 of human NgR1 (SEQ ID NO:4);
- (c) amino acids 27 to 310 of rat NgR1 (SEQ ID NO:5); and
- (d) amino acids 27 to 344 of rat NgR1 (SEQ ID NO:6).

Claim 59. The method of claim 56, wherein the soluble form of a mammalian NgR1 further comprises a fusion moiety.

Claim 60. The method of claim 52, wherein the therapeutically effective amount is from 0.001 mg/kg to 10 mg/kg of soluble Nogo receptor polypeptide.

Claim 61. A method for reducing the levels of A $\beta$  peptide in a mammal, comprising administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to a mammalian NgR1.